Cargando…
HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors
Autores principales: | Yoneshima, Yasuto, Kato, Koji, Minami, Haruna, Ikeda, Munehiko, Watanabe, Hiroyuki, Yoshimoto, Goichi, Miyamoto, Toshihiro, Akashi, Koichi, Nakanishi, Yoichi, Okamoto, Isamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469807/ https://www.ncbi.nlm.nih.gov/pubmed/32557883 http://dx.doi.org/10.1111/cas.14536 |
Ejemplares similares
-
Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β
por: Hirayama, Aiko, et al.
Publicado: (2023) -
(18)F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer
por: Takada, Kazuki, et al.
Publicado: (2019) -
A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
por: Takada, Kazuki, et al.
Publicado: (2022) -
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer
por: Ibusuki, Ritsu, et al.
Publicado: (2022) -
Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
por: Ando, Nobuhisa, et al.
Publicado: (2020)